Neogenomics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
57.4%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$804.1Mnext fiscal year
FY EPS (est.)
$0.18next fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Revenue Quarterly186.7MTarget: 797000000 to 803000000
Adjusted EBITDA Quarterly9MTarget: 55000000 to 57000000
Next-Generation Sequencing (NGS) Revenue Growth Quarterly26.0%
Watch Items
- PanTracer LBx Medicare Reimbursement and Commercial ScalingTrigger: MolDX reimbursement coverage under LCD L38043Action: Monitor clinical volume uptake and average unit price (AUP) expansion through 2026.
- RaDaR ST MRD Assay Commercial AdoptionTrigger: Full clinical launch completed in February 2026Action: Track sales force expansion (adding 25+ oncology sales specialists) and market penetration in the $20B MRD market.
- Pharma Services Segment PerformanceTrigger: Non-clinical revenue decline of 15% YoY in Q1 2026Action: Assess stabilization of biopharma and biotech client spending to mitigate non-clinical headwinds.
Research as of 20 Jun 2026